Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir

Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development. However, the risk of resistance development threatens the future efficacy of such direct-acting antivirals. T...

Full description

Bibliographic Details
Main Authors: Karen Anbro Gammeltoft, Yuyong Zhou, Line Abildgaard Ryberg, Long V. Pham, Alekxander Binderup, Carlos Rene Duarte Hernandez, Anna Offersgaard, Ulrik Fahnøe, Günther Herbert Johannes Peters, Santseharay Ramirez, Jens Bukh, Judith Margarete Gottwein
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Viruses
Subjects:
SARS-CoV-2
COVID-19
antiviral resistance
protease inhibitor
boceprevir
nirmatrelvir
Online Access:https://www.mdpi.com/1999-4915/15/9/1970

Internet

https://www.mdpi.com/1999-4915/15/9/1970

Similar Items